PortalPublikationenTreatment with Thalidomide and Cyclophosphamide (TCID) is Su...

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

Standard

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma. / Auel, Britta; Goldschmidt, Hartmut; Geer, Thomas; Moehler, Thomas M; Platzbecker, Uwe; Naumann, Ralph; Blau, Igor; Hänel, Mathias; Knauf, Wolfgang; Nückel, Holger; Salwender, Hans-Jürgen; Scheid, Christof; Weisel, Katja; Gorschlüter, Marcus; Glasmacher, Axel; Schmidt-Wolf, Ingo G H; German Refractory Myeloma Study Group.

in: INDIAN J HEMATOL BLO, Jahrgang 28, Nr. 2, 06.2012, S. 67-76.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Auel, B, Goldschmidt, H, Geer, T, Moehler, TM, Platzbecker, U, Naumann, R, Blau, I, Hänel, M, Knauf, W, Nückel, H, Salwender, H-J, Scheid, C, Weisel, K, Gorschlüter, M, Glasmacher, A, Schmidt-Wolf, IGH & German Refractory Myeloma Study Group 2012, 'Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma', INDIAN J HEMATOL BLO, Jg. 28, Nr. 2, S. 67-76. https://doi.org/10.1007/s12288-011-0103-1

APA

Auel, B., Goldschmidt, H., Geer, T., Moehler, T. M., Platzbecker, U., Naumann, R., Blau, I., Hänel, M., Knauf, W., Nückel, H., Salwender, H-J., Scheid, C., Weisel, K., Gorschlüter, M., Glasmacher, A., Schmidt-Wolf, I. G. H., & German Refractory Myeloma Study Group (2012). Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma. INDIAN J HEMATOL BLO, 28(2), 67-76. https://doi.org/10.1007/s12288-011-0103-1

Vancouver

Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R et al. Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma. INDIAN J HEMATOL BLO. 2012 Jun;28(2):67-76. https://doi.org/10.1007/s12288-011-0103-1

Bibtex

@article{51aa08eb1d8c45d2bdccf5b69faae9e8,
title = "Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma",
abstract = "Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.",
keywords = "Journal Article",
author = "Britta Auel and Hartmut Goldschmidt and Thomas Geer and Moehler, {Thomas M} and Uwe Platzbecker and Ralph Naumann and Igor Blau and Mathias H{\"a}nel and Wolfgang Knauf and Holger N{\"u}ckel and Hans-J{\"u}rgen Salwender and Christof Scheid and Katja Weisel and Marcus Gorschl{\"u}ter and Axel Glasmacher and Schmidt-Wolf, {Ingo G H} and {German Refractory Myeloma Study Group}",
year = "2012",
month = jun,
doi = "10.1007/s12288-011-0103-1",
language = "English",
volume = "28",
pages = "67--76",
journal = "INDIAN J HEMATOL BLO",
issn = "0971-4502",
publisher = "Springer India",
number = "2",

}

RIS

TY - JOUR

T1 - Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma

AU - Auel, Britta

AU - Goldschmidt, Hartmut

AU - Geer, Thomas

AU - Moehler, Thomas M

AU - Platzbecker, Uwe

AU - Naumann, Ralph

AU - Blau, Igor

AU - Hänel, Mathias

AU - Knauf, Wolfgang

AU - Nückel, Holger

AU - Salwender, Hans-Jürgen

AU - Scheid, Christof

AU - Weisel, Katja

AU - Gorschlüter, Marcus

AU - Glasmacher, Axel

AU - Schmidt-Wolf, Ingo G H

AU - German Refractory Myeloma Study Group

PY - 2012/6

Y1 - 2012/6

N2 - Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.

AB - Treatment of relapsed or refractory multiple myeloma remains a challenge and novel treatment regimen are required. Here, a matched pair analysis was performed comparing TCID (thalidomide, cyclophosphamide, idarubicin, dexamethasone) treatment to the treatment of patients with VID (vincristine, idarubicin, dexamethasone) or with VRID (vinorelbine, idarubicin, dexamethasone) for relapsed or refractory multiple myeloma. In total, 197 patients were enrolled in multicenter trials. After matching for important prognostic variables 46 matched-pairs (total of 138 patients) could be analysed with regard to survival, toxicity and efficacy. Interestingly, a significant improvement of overall response rate (ORR) for TCID treatment compared to VID and VRID was found. In addition, TCID treatment also led to a significantly higher overall survival (OS) as well as progression-free survival (PFS) compared to VID and VRID. In conclusion, TCID treatment appears to be superior to VRID and VID treatment in patients with progressive or refractory myeloma.

KW - Journal Article

U2 - 10.1007/s12288-011-0103-1

DO - 10.1007/s12288-011-0103-1

M3 - SCORING: Journal article

C2 - 23730012

VL - 28

SP - 67

EP - 76

JO - INDIAN J HEMATOL BLO

JF - INDIAN J HEMATOL BLO

SN - 0971-4502

IS - 2

ER -